Lonza is a Swiss contract development and manufacturing organization serving pharma and biotech customers. It produces biologics, small molecules and advanced modalities such as cell and gene therapies under long-term manufacturing partnerships. Clients range from large drugmakers to emerging biotechs that outsource process development and commercial-scale supply rather than building plants themselves.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 6,223 | — | 1,215 | — |
| 2023 | 6,717 | 7.9% | 654 | -46.2% |
| 2024 | 5,480 | -18.4% | 636 | -2.8% |
| 2025 | 6,531 | 19.2% | -275 | -143.2% |
All markets — KeepWinning global stock screener
Other companies on SMI: Holcim Limited (HOLN), Swisscom AG (SCMN), Sika AG (SIKA), Givaudan SA (GIVN), Alcon Inc (ALC), Swiss Life Holding AG (SLHN)